Reprint
Cellular and Molecular Mechanisms Underlying the Pathogenesis of Hepatic Fibrosis
Edited by
August 2020
276 pages
- ISBN978-3-03936-188-5 (Hardback)
- ISBN978-3-03936-189-2 (PDF)
This book is a reprint of the Special Issue Cellular and Molecular Mechanisms Underlying the Pathogenesis of Hepatic Fibrosis that was published in
Biology & Life Sciences
Medicine & Pharmacology
Summary
Worldwide, liver fibrosis is a major cause of morbidity and mortality and is associated with a high medical and economic burden. It is the common consequence of chronic liver injury due to various etiologies. During fibrogenesis, there is a progressive substitution of the liver parenchyma by scar tissue. Recent advances in the understanding of the history of liver fibrosis have shown that the pathogenesis is driven by different cell types and a large variety of soluble mediators. At present, scientists working in this field aim to increase basic knowledge, improve diagnostics, and try to translate experimental findings into new treatment modalities. This book includes 12 selected contributions from the Special Issue “Cellular and Molecular Mechanisms Underlying the Pathogenesis of Hepatic Fibrosis” that was published in Cells. These articles summarize current perspectives and findings in hepatic fibrosis research showing how scientists try to use basic scientific research to create new therapies and diagnostics.
Format
- Hardback
License
© 2020 by the authors; CC BY-NC-ND license
Keywords
xanthohumol; micellar solubilisation; obesity; diabetes; non-alcoholic fatty liver disease; BMP8B; steatosis; inflammation; NAFLD; non-alcoholic fatty liver disease; hepatic stellate cells; myofibroblasts; liver fibrosis; scRNASeq; nonalcoholic steatohepatitis; fibrosis; grading; staging; imaging; algorithms; scores; biomarkers; PLA2G6; endoplasmic reticulum; phospholipids; bile acids; lean NASH; unfolded protein response; biomarker; NAFLD; viral liver disease; alcoholic liver disease; microRNA; hepatic stellate cell; fibrosis; diagnosis; liquid biopsy; steatosis; cirrhosis; hepatic fibrosis; portal hypertension; steatohepatitis; dipeptidyl peptidase-4 inhibitors; hepatic stellate cells; oleanolic acid; Takeda G protein-coupled receptor 5; hepatic stellate cells; hepatic fibrosis; vimentin; Rho; ERK; AKT; fibrocytes; liver fibrosis; bone marrow; myofibroblasts; thioacetamide (TAA); HSV-TK; non-alcoholic fatty liver disease (NAFLD); steatosis; mitochondria; mitochondrial DNA (mtDNA); oxidative phosphorylation (OXPHOS); ADAM; protease; EGFR; hepatic stellate cell; liver fibrosis; hepatitis C virus; hepatic stellate cells; fibrosis; exosomes; non-coding RNAs; nonalcoholic fatty liver disease; nonalcoholic steatohepatitis; gender disparity in liver response; estrogen; liver inflammation; liver fibrosis; gender-based therapy; RhoA-ROCK; fasudil; Th17; Schistosoma japonicum; hepatic fibrosis; angiogenesis; inflammation; non-alcoholic fatty liver disease; fatty liver; steatosis; RUNX1; liver fibrosis; magnetic fields; nanomedicines; immune cells; macrophages; hepatic stellate cells; RNA-based medicines; drug delivery; magnetic nanoparticles; microRNA-29a; steatohepatitis; fibrosis; CD36; endocannabinoids; apelin; liver fibrosis; CB1; CB2; APJ; fibrosis; cirrhosis; alcoholic liver disease; NAFLD; NASH; intestinal permeability; bacterial translocation; innate immunity; Akt1; Akt2; Akt3; Akt isoforms; alcoholic liver disease; liver fibrosis; inflammation; proliferation; migration; liver fibrosis; cell therapy; stem cells; progenitor cells; hepatocytes; secretome; in vitro; liver fibrosis; natural products; sulfur-containing compounds; glutathione; sulforaphane; lipoic acid; taurine; ergothioneine; ovothiol; garlic; bile acids; bile acid metabolism; NAFLD/NASH therapy; lipid metabolism; gut-liver axis; UDCA; OCA; hepatitis C virus; hepatocellular carcinoma (HCC); invasion; metastasis; HCV; HCC; hepatocellular carcinoma; fibrosis; oxidative phosphorylation; mitochondrial respiratory chain; NADH-ubiquinone oxidoreductase; cytochrome c oxidase; ATP-Synthase; warburg effect; iron metabolism; α1-antitrypsin deficiency; rare liver disease; genetic liver disease; SERPINA1; HFE; liver fibrosis; hepatic fibrosis; HSC; aerobic glycolysis; Fischer’s ratio; TCA cycle; transcriptomics; proteomics; metabolomics; liver; inflammation; fibrosis; mast cell; degranulation; TGF-β; animal models; translational medicine; chymase; tryptase; clusterin; hepatic stellate cells; hepatic fibrosis; Smad3; bile acids; endothelin-1; sinusoidal endothelial cells; hepatic stellate cells; portal hypertension; cell adhesion; liver fibrosis; selectin; integrin; cadherin; immunoglobulin superfamily; junctional adhesion molecule; non-classical adhesion molecule; antifibrotic therapy; oxaliplatin; non-cirrhotic portal hypertension; porto sinusoidal vascular disease; Pin1; NASH; NAFLD; fibrosis; lipid; inflammation; zonation; liver lobule; chronic liver disease; cytochrome P450; inflammation; bile duct ligation; acetaminophen; Ubiquitination; NEDDylation; SUMOylation; HCC; chronic liver disease; NAFLD; NASH; liver fibrosis; hepatic stellate cell; trans-differentiation; metabolism; Oncostatin M; liver fibrosis; NAFLD/NASH; myofibroblasts; migration; reactive oxygen species; VEGF-A; inflammation; macrophages; innate immunity; innate immune memory; histones; epigenetics; four-and-a-half LIM-domain protein 2; FHL2; cholestatic liver injury; bile acids; cholestasis; liver fibrosis; bile salts; hepatic stellate cell; EGFR; extracellular vesicle; hepatic stellate cell; hepatic fibrosis; exosome; microvesicle; liver; liver cirrhosis; liver sinusoidal permeability; liver sinusoidal endothelial cells; hepatic stellate cells; beta secretase; presenilin; endothelial nitric oxide synthase; myelin basic protein; Alzheimer’s disease; neprilysin; astrocytes; α2-adrenoceptors; norepinephrine; mesedin; hepatic stellate cells; sinusoidal endothelial cells; liver fibrosis; sinusoidal permeability; liver inflammation; liver fibrosis; sterile inflammation; inflammasome; DAMPs; heart failure; arrhythmia; congestive hepatopathy; cardiogenic ischemic hepatitis; cirrhotic cardiomyopathy; liver transplantation; nonalcoholic fatty liver disease; Hepatic stellate cell; liver myofibroblast; Kupffer cell; liver cirrhosis; anti-fibrotics; TGF-β; PDGF; ATP; P2X7 receptor; NAFLD; NASH; liver; fibrosis; n/a